Hercules Capital, Inc.
HTGCHercules Capital, Inc. (HTGC) is a specialty finance company that provides debt and equity financing to technology, life sciences, and broader venture growth companies. Founded in 2003, the firm primarily focuses on early and growth-stage companies, offering customized capital solutions to support their development and expansion efforts. Hercules Capital is known for its sector expertise and attention to innovation-driven markets.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| November 19, 2025 | $0.07 | 2025-11-12 | 2025-11-12 |
| November 19, 2025 | $0.40 | 2025-11-12 | 2025-11-12 |
| August 19, 2025 | $0.07 | 2025-08-12 | 2025-08-12 |
| August 19, 2025 | $0.40 | 2025-08-12 | 2025-08-12 |
| May 20, 2025 | $0.07 | 2025-05-13 | 2025-05-13 |
Dividends Summary
- Hercules Capital, Inc. has issued 108 dividend payments over the past 20 years
- The most recent dividend was paid 19 days ago, on November 19, 2025
- The highest dividend payed out to investors during this period was $0.40 per share
- The average dividend paid during this period was $0.25 per share.
Company News
MoonLake Immunotherapeutics reported Q3 2025 financial results, highlighting positive clinical trial data for its Nanobody® sonelokimab in treating inflammatory diseases like hidradenitis suppurativa, psoriatic arthritis, and palmoplantar pustulosis. The company ended the quarter with $380.5 million in cash and expects funding into the second ha...
Sound Income Strategies sold 177,473 shares of Hercules Capital for approximately $3.40 million in Q3 2025, reducing its stake while maintaining over 2.7 million shares. Hercules Capital has underperformed the S&P 500 over the past year.
Hercules Capital Inc.'s Q2 2024 net investment income matched estimates, but declined year-over-year due to higher operating expenses. The company's total investment income and portfolio value remained strong, but expenses rose due to increased interest and compensation costs.
Eloxx Pharmaceuticals, a biopharmaceutical company, has secured an additional $3.175 million in funding through a loan agreement amendment with Hercules Capital and other lenders. The funding will be used for the company's operations and development of its ELX-02 compound.
Related Companies
